ObesityWeek 2026 ran November 14–17 in Washington, DC, and the next generation of weight-loss drugs is closer, but none of the drugs below is FDA-approved today. Here’s where each one stands as of November 21, 2026, with the source for every date and number.
Status at a glance
| Drug | Company | What it is | Status (Nov 21, 2026) |
|---|---|---|---|
| CagriSema | Novo Nordisk | Weekly injection: cagrilintide (amylin analog) + semaglutide | FDA application filed Dec 2025; decision expected Q4 2026 |
| Retatrutide | Eli Lilly | Weekly injection: GIP, GLP-1 and glucagon receptor agonist | Phase 3 results reported; FDA filing planned Q1 2027 |
| Eloralintide | Eli Lilly | Weekly injection: amylin receptor agonist | Phase 3 trials registered |
| Amycretin (zenagamtide) | Novo Nordisk | GLP-1 and amylin receptor agonist | Phase 3 (AMAZE) program initiated 2026 |
CagriSema: an FDA decision is due
CagriSema combines semaglutide, the active ingredient in Wegovy, with cagrilintide, a long-acting version of amylin, a hormone the pancreas releases alongside insulin. Novo Nordisk filed its New Drug Application for CagriSema 2.4 mg / 2.4 mg in December 2025. In its November 14, 2026 release, Novo said “a decision is expected in Q4 2026” and that CagriSema “is not approved for use in the United States.”
What the trials show:
- REDEFINE 1 (NEJM, 2025): 3,417 adults without diabetes; average weight change at 68 weeks was −20.4% with CagriSema.
- REDEFINE 9 (presented at ObesityWeek and published in The Lancet Diabetes & Endocrinology, November 14, 2026): two lower doses, 1.7/1.7 mg and 1.0/1.0 mg, produced 19.4% and 18.6% average weight loss at 68 weeks versus 4.6% on placebo, counting everyone regardless of whether they stopped treatment. If everyone had stayed on treatment, Novo estimates 20.7% and 21.0% versus 2.0%. The most common side effects were gastrointestinal and mostly mild to moderate.
If approved, CagriSema would join the semaglutide family. For what semaglutide costs today, see our Wegovy cost breakdown.
Retatrutide: filing planned for early 2027
Retatrutide is Lilly’s “triple agonist.” It acts on three hormone receptors (GIP, GLP-1, and glucagon) instead of one or two. On July 23, 2026, Lilly reported topline results from two more Phase 3 trials and said retatrutide has now succeeded in five Phase 3 studies:
- TRIUMPH-2 (adults with obesity or overweight and type 2 diabetes): average weight loss at 80 weeks of 12.7%, 19.1%, and 20.8% on the 4 mg, 9 mg, and 12 mg doses, versus 4.0% on placebo, with A1C reductions of up to 1.6 points.
- TRIUMPH-3 (adults with severe obesity and established cardiovascular disease): up to 22.6% average weight loss at 80 weeks.
Lilly says it plans to submit a Biologics License Application to FDA in the first quarter of 2027. Approval would come after FDA’s review, so there is no launch date.
FDA has been unusually direct about retatrutide sold online. Its consumer page on unapproved GLP-1 drugs, last updated October 1, 2026, says retatrutide “cannot be used in compounding under federal law,” is not a component of any approved drug, and that the agency has warned telehealth companies, ingredient distributors, and outsourcing facilities over it. See how it compares to today’s approved options in tirzepatide vs. retatrutide.
Eloralintide: Lilly’s amylin drug enters Phase 3
Eloralintide (LY3841136) targets the amylin receptor, the same pathway as cagrilintide. Lilly has registered several Phase 3 trials on ClinicalTrials.gov, including once-weekly eloralintide versus placebo in adults with obesity or overweight with and without type 2 diabetes, in people with obstructive sleep apnea, and in people still living with obesity while on a weekly incretin. Results will take time; these trials are just getting underway.
Amycretin (zenagamtide): one molecule, two targets
Amycretin, which Novo Nordisk now calls zenagamtide, is a single molecule that acts on both GLP-1 and amylin receptors, rather than combining two drugs the way CagriSema does. Novo’s first-quarter 2026 investor presentation lists the zenagamtide AMAZE Phase 3 program as initiated.
What you can use today
While the pipeline matures, two FDA-approved GLP-1 pills joined the injections this year:
- Wegovy pill (oral semaglutide), approved December 22, 2025
- Foundayo (orforglipron), approved April 1, 2026 (how the two pills compare)
Injectable options include Wegovy and Zepbound, both with manufacturer self-pay programs. Our GLP-1 pricing hub lists current, sourced prices for each, and our Zepbound cost page covers Lilly’s self-pay tiers. Ready to talk to a prescriber? Compare GLP-1 providers.
Last updated November 21, 2026. We’ll update this page when FDA decides on CagriSema or Lilly files retatrutide.
